Tag: ASX: CAN
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
